Going forward, we believe a comprehensive study on keratinocytes treated with cytokines representing other inflammatory profiles, including type 1 (IFNγ) and type 3 (IL-17A and IL-22), would identify whether our findings are unique to type 2 inflammation (IL-4/13) or could be attributed to other inflammatory skin diseases. This evidence concerns the gene IL22 and inflammatory skin disease.